Evaluation of whole sporozoite vaccines for...

In the News

Article: Window screens can suppress malaria

(Dar es Salaam & Liverpool) Protecting houses against mosquitoes with netting window screens can suppress malaria, IHI scientists have confirmed. In an article published today in Lancet Planetary Health, a …

IHI scientists in Dodoma for Water Week

(Dodoma) TWO IHI scientists, Alfred Boniphace and Dr. Beda Levira, represented the Institute in this year’s Water Week commemorations which was held at the national level in Dodoma during the …

Recent Projects

Calcium supplementation on pregnant women

Project summary This is a trial-based study funded by the Bill and Melinda Gates Foundation. It intends to generate evidence for decision-making on the potential non-inferiority of a lower dose …

Sustainable, Healthy, Learning Cities and Neighbourhoods

The Sustainable, Healthy, Learning Cities and Neighbourhoods is an exciting project in which IHI works with a consortium of partners from Asia and Africa to 1) develop capacity for improved …

Evaluation of whole sporozoite vaccines for malaria elimination

This program of work is led by a clinical team at the Ifakara Health Institute Clinical Trial Facility at Kingani, Bagamoyo (IHI – CTF) which is conducting a series of studies to evaluate the potential impact of whole sporozoite malaria vaccine candidates to prevent malaria infection and thereby block transmission with the goal of achieving malaria elimination in Sub-Sahara Africa. The work is conducted in two countries; Tanzania and Equatorial Guinea. Studies and major contributions of the work to date include:

dr-omar-in-the-labBSPZC1 (NCT01540903): The first Controlled Human Malaria Infection (CHMI) study using purified fully infectious malaria sporozoites in an African country was conducted at IHI-CTF at Kingani, Bagamoyo in 2012. This trial demonstrated the safety and infectivity of the fully infectious purified sporozoites (PfSPZ Challenge) leading to the establishment of the CHMI model for testing new malaria vaccines and drugs in Africa

BSPZV1 (NCT02132299): Study conducted in IHI-CTF at Kingani, Bagamoyo between 2014-2015. This was the first PfSPZ Vaccine (radiation attenuated sporozoites) trial to be conducted in Africa. The trial established a very good safety and tolerability profile for the PfSPZ vaccine and was the basis for further studies in Mali and Equatorial Guinea.

BSPZV2 (NCT02613520): Study conducted in IHI-CTF at Kingani, Bagamoyo between 2015- 2016. Worldwide, this was the first PfSPZ Vaccine (radiation attenuated sporozoites) trial in adolescents and children. The trial established a very good safety and tolerability profile for PFSPZ vaccine in younger age groups and well as better immune responses in younger children. This work was the basis for further studies in Equatorial Guinea, Kenya and other African countries.

Partners

Swiss Tropical and Public Health Institute
Sanaria Inc.

Funders

The government of Equitorial Guinea, Marathon Oil, Noble Energy and AMPCO
Medicines for Malaria Ventures (MMV)

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016